medRxiv PreprintsInternational20 November 2026
Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Slow-wave sleep (SWS) has been implicated in memory consolidation and brain plasticity and proposed as a therapeutic target in major depressive disorder (MDD). However, whether pharmacological promotion of SWS causally improves memory consolidation remains unknown. Gamma-hydroxybutyrate (GHB), a robust enhancer of SWS, represents a promising drug-repurposing candidate to target this pathway. We therefore conducted a randomized, double-blind, placebo-controlled crossover trial in 22 patients with MDD and 20 matched healthy controls receiving single nocturnal doses of GHB, trazodone as an active
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
- Elevated maternal hemoglobin levels during pregnancy are associated with autism spectrum disorder in the offspring: A population-based cohort study20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.